My IDSA Contact Us

Print-Friendly Newsletter Forward to a Friend Search Back Issues

Education & Training Resources Practice Guidlines Journals & Publications Policy & Advocacy Meetings About IDSA

May 1, 2008 FDA Lowers Vancomycin Breakpoints for Staph Infections The Food and Drug Administration (FDA) has lowered the breakpoints for vancomycin in the treatment of Staphylococcus aureus to reflect growing rates of resistance, and in response to urging from IDSA and others.  WHO Reports Progress on Dracunculiasis Eradication The end is in sight for the global campaign to eradicate dracunculiasis (guinea-worm disease), but daunting challenges still remain in endemic areas of Mali and Sudan, according to the World Health Organization.  IDSA Literature Review - April 2008 In this new feature, a panel of IDSA members identifies and critiques important new infectious diseases studies in the current literature that have a significant impact on the practice of infectious diseases medicine. Brazil Has Large Dengue Fever Outbreak Malaria Reported in Bahamas Polio Eradication Update: Cases Down Overall, But Type 3 Cases Up Rift Valley Fever Outbreak in Madagascar Vietnam Reports Cholera Outbreak Yellow Fever Reported in Liberia, Argentina Cefixime Available Again in the United States Drug Approvals, Recalls, Adverse Events Update In the IDSA Journals From the President IDSA Endorses Two Vaccine Financing Bills IDSA Urges FDA to Dedicate Resources to Antimicrobial Resistance Members on the Move Welcome, New IDSA Members! FDA Lowers Vancomycin Breakpoints for Staph Infections WHO Reports Progress on Dracunculiasis Eradication IDSA Literature Review - April 2008 Brazil Has Large Dengue Fever Outbreak Malaria Reported in Bahamas Polio Eradication Update: Cases Down Overall, But Type 3 Cases Up Rift Valley Fever Outbreak in Madagascar Vietnam Reports Cholera Outbreak Yellow Fever Reported in Liberia, Argentina Cefixime Available Again in the United States Drug Approvals, Recalls, Adverse Events Update In the IDSA Journals From the President IDSA Endorses Two Vaccine Financing Bills IDSA Urges FDA to Dedicate Resources to Antimicrobial Resistance Members on the Move Welcome, New IDSA Members!

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200

To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List. If you are still having problems receiving our communications, see our white-listing page for more details. Unsubscribe here